The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human α V β 3 Integrin via Steric Hindrance

Abstract : The LM609 antibody specifically recognizes αVβ3 integrin and inhibits angiogenesis, bone resorption, and viral infections in an arginine-glycine-aspartate-independent manner. LM609 entered phase II clinical trials for the treatment of several cancers and was also used for αVβ3-targeted radioimmunotherapy. To elucidate the mechanisms of recognition and inhibition of αVβ3 integrin, we solved the structure of the LM609 antigen-binding fragment by X-ray crystallography and determined its binding affinity for αVβ3. Using single-particle electron microscopy, we show that LM609 binds at the interface between the β-propeller domain of the αV chain and the βI domain of the β3 chain, near the RGD-binding site, of all observed integrin conformational states. Integrating these data with fluorescence size-exclusion chromatography, we demonstrate that LM609 sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. This work provides a structural framework to expedite future efforts utilizing LM609 as a diagnostic or therapeutic tool.
Type de document :
Article dans une revue
Structure, Elsevier (Cell Press), 2017, 25 (11), pp.1732 - 1739.e5. 〈10.1016/j.str.2017.09.007〉
Liste complète des métadonnées

https://hal-pasteur.archives-ouvertes.fr/pasteur-01632900
Contributeur : Marija Backovic <>
Soumis le : vendredi 10 novembre 2017 - 17:02:45
Dernière modification le : jeudi 11 janvier 2018 - 06:25:35

Identifiants

Collections

Citation

Andrew Borst, Zachary M. James, William N. Zagotta, Mark Ginsberg, Félix A. Rey, et al.. The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human α V β 3 Integrin via Steric Hindrance. Structure, Elsevier (Cell Press), 2017, 25 (11), pp.1732 - 1739.e5. 〈10.1016/j.str.2017.09.007〉. 〈pasteur-01632900〉

Partager

Métriques

Consultations de la notice

15